Feb 23, 2017

Here's why PhRMA sees hope for "value-based" payments

Ron Sachs / Pool via CNP /MediaPunch/IPX

The Pharmaceutical Research and Manufacturers of America, the main drug industry trade group, has been pushing for changes to the way insurers pay for drugs — encouraging them to pay based on how effective they are for specific diseases and patients. Now, the group says it's more optimistic about getting the legislative and regulatory changes that would be needed, following its meeting with President Trump last month.

"It did come up," PhRMA president and CEO Stephen Ubl told reporters this morning after an event to promote the idea. He wouldn't talk in more detail about the Trump meeting, but he suggested the idea might be gaining traction as an alternative to having the government negotiate drug prices, as Trump has also suggested: "I do believe that people believe that this is a policy that enhances the private market and is a potential better route than government price setting."

Why it matters: The drug industry would much rather have the "value-based" payments as a way to make drugs more affordable, rather than government action. But there are barriers that would have to be removed, and Ubl says that probably will take a combination of congressional action and regulatory changes from the Food and Drug Administration. Ubl said the group is talking with members of Congress from both parties, but he also says a new FDA commissioner "will make a real difference."

Go deeper

The cost of going after Bloomberg

Illustration: Eniola Odetunde/Axios

Here's the growing dilemma for 2020 Democrats vying for a one-on-one showdown with frontrunner Bernie Sanders: Do they have the guts — and the money — to first stop Mike Bloomberg?

Why it matters: Joe Biden, Pete Buttigieg, Amy Klobuchar and Elizabeth Warren all must weigh the costs of punching Bloomberg where he looks most vulnerable: stop-and-frisk, charges of sexism, billionaire entitlement. The more zealous the attacks, the greater the risk he turns his campaign ATM against them.

How Trump’s economy stacks up

Source: "Presidents and US Economy", Trump figures through 2019 courtesy of Alan Blinder; Note: Data shows real GDP and Q1 growth in each term is attributed to the previous president; Chart: Axios Visuals

Average economic growth under President Trump has outpaced the growth under Barack Obama, but not all of his recent predecessors.

Why it matters: GDP is the most comprehensive economic scorecard — and something presidents, especially Trump, use as an example of success. And it's especially relevant since Trump is running for re-election on his economic record.

Coronavirus cases rise as 14 American evacuees infected

Data: The Center for Systems Science and Engineering at Johns Hopkins, the CDC, and China's NHC; Note: China refers to mainland China and the Diamond Princess is the cruise ship offshore Yokohama, Japan. Map: Danielle Alberti/Axios

14 Americans evacuated from the Diamond Princess cruise ship tested positive for the novel coronavirus before being flown in a "specialist containment" on a plane repatriating U.S. citizens back home, the U.S. government said early Monday.

The big picture: COVID-19 has now killed at least 1,770 people and infected almost 70,000 others. Most cases and all but five of the deaths have occurred in mainland China. Taiwan confirmed its first death on Sunday, per multiple reports, in a 61-year-old man with underlying health conditions. Health officials were investigating how he became ill.

Go deeperArrowUpdated 5 hours ago - Health